Do patients above 70 years of age with newly diagnosed advanced non–small-cell lung cancer benefit from platinum-based combination or should they receive non-platinum agents either as single-agent or in combination?
For fit elderly patients platinum-based combination is associated with better overall survival, progression-free survival, and objective response rate, however this improvement should be counter balanced against the higher risk of major adverse events (AE).
Santos FN, Cruz MRS, Riera R. Chemotherapy for Advanced Non–Small-Cell Lung Cancer in Elderly Patients. JAMA Oncol. 2016;2(12):1645–1646. doi:10.1001/jamaoncol.2016.2050
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.